wyniki za 2024 - komunikat spółki KRKA, TOVARNA ZDRAVIL D.D. (krka) - komunikat ESPI

Komunikat spółki

COMMON REPORT

	POLISH FINANCIAL SUPERVISION AUTHORITY
				UNI - EN REPORT No		4	/	2025
	Date of issue:		2025-01-30
	Short name of the issuer
	KRKA
	Subject
	2024 Krka Group Performance Estimate
	Official market - legal basis
	art. 17. 1 MAR.
	Unofficial market - legal basis
	Contents of the report:
	Based on the provisions of Article 26 of the Ljubljana Stock Exchange Rules, Article 158 of the Market in Financial Instruments Act, and Article 17 of Regulation (EU) No 596/2014, Krka, d. d., Novo mesto (hereinafter: Krka) releases the 2024 unaudited performance estimates for the Krka Group. The press releases with 2024 Krka Group performance estimate is attached. This announcement will be published on the company s website (www.krka.biz) starting from 30 January 2025, for a minimum period of 5 years.
	Annexes
	File				Description
	Krka Group 2024 Performance Estimate.pdf				Krka Group 2024 Performance Estimate

KRKA, TOVARNA ZDRAVIL D.D.

(fullname of the issuer)

KRKA

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification of the WSE in Warsow)

8501

Nove Mesto

(post code)

(city)

Smarjeska

6

(street)

(number)

+386 7 331 21 11

+386 7 332 15 37

(phone number)

(fax)

(e-mail)

(web site)

nie dotyczy

(NIP)

(REGON)

	SIGNATURE OF PERSONS REPRESENTING THE COMPANY
	Date	Name	Position / Function	Signature
	2025-01-30	Jože Colarič	President of the Management Board and CEO

Nazwa jednostki:	KRKA, TOVARNA ZDRAVIL D.D.
Nazwa skrócona jednoskti:	KRKA
Adres:	Smarjeska 6, 8501 Nove Mesto
Telefon:	+386 7 331 21 11
Fax:	+386 7 332 15 37
NIP:	nie dotyczy